Evidence map›Paper›PMID 29904102›Full record

ArticleOncogene2018

Targeting PRPK and TOPK for skin cancer prevention and therapy.

Eunmiri Roh, Mee-Hyun Lee, Tatyana A Zykova, Feng Zhu, Janos Nadas, Hong-Gyum Kim, Ki Beom Bae, Yan Li, Yong Yeon Cho, Clara Curiel-Lewandrowski and 4 more

Abstract read
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. The Therapeutic Role of Genistein in Perimenopausal and Postmenopausal Women.The Journal of clinical and aesthetic dermatology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Eunmiri RohThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Mee-Hyun LeeThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Tatyana A ZykovaThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Feng ZhuThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Janos NadasThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Hong-Gyum KimThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Ki Beom BaeThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Yan LiThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Yong Yeon ChoCollege of Pharmacy, The Catholic University of Korea, Bucheon, 420-743, Korea.
Clara Curiel-LewandrowskiUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Janine EinspahrUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Sally E DickinsonUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.
Zigang DongThe Hormel Institute, University of Minnesota, Austin, MN, 55912, USA. zgdong@hi.umn.edu.
University of Minnesota · USHormel (United States) · USUniversity of Arizona · USCatholic University of Korea · KRHuazhong University of Science and Technology · CNUniversity of Arizona Cancer Center

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
VITAMIN A, AND ITS PRECURSORS AND DERIVATIVES AS THERAPEUTIC MODALITIESP01CA027502 · NCI · UNIVERSITY OF ARIZONA · PI BOWDEN, TIMOTHY · 1985 to 2015
$36.3M
Chemoprevention of colon cancer by targeting the Wnt/beta-catenin pathwayR01CA187027 · NCI · UNIVERSITY OF MINNESOTA · PI KANG, NINGLING, ROH, EUNMIRI · 2015 to 2019
$1.7M
Prevention of solar UV-induced skin cancer by targeting LTA4HR01CA196639 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, LIANG · 2015 to 2019
$1.7M
Developing new ornithine decarboxylase inhibitors to prevent skin & colon cancerR01CA166011 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2017
$1.6M
NCI NIH HHS P01 CA027502NCI NIH HHS R01 CA166011NCI NIH HHS R01 CA187027NCI NIH HHS R01 CA196639U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA027502U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA166011U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA196639
6 · The paper itself

Abstract

Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that can cause inflammation and skin cancer. The costs and morbidity associated with skin cancer are increasing, and therefore identifying molecules that can help prevent skin carcinogenesis is important. In this study, we identified the p53-related protein kinase (PRPK) as a novel oncogenic protein that is phosphorylated by the T-LAK cell-originated protein kinase (TOPK). Knockdown of TOPK inhibited PRPK phosphorylation and conferred resistance to solar-simulated light (SSL)-induced skin carcinogenesis in mouse models. In the clinic, acute SSL irradiation significantly increased epidermal thickness as well as total protein and phosphorylation levels of TOPK and PRPK in human skin tissues. We identified two PRPK inhibitors, FDA-approved rocuronium bromide (Zemuron

Indexed as

AnimalsBetamethasone ValerateCarcinogenesisCarcinoma, Squamous CellEnzyme InhibitorsHumansMiceMice, HairlessMitogen-Activated Protein Kinase KinasesProtein Serine-Threonine KinasesRocuroniumSkin NeoplasmsUltraviolet RaysBetamethasone ValerateEnzyme InhibitorsMitogen-Activated Protein Kinase KinasesProtein Serine-Threonine KinasesRocuronium

Identifiers

PMID29904102
PMCPMC6195829
OpenAlexW2808522519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.